Ma et al. [108] established a mouse model of cardiomyopathy induced by peritoneal doxorubicin injection (10 mg/kg) and found that blocking the activity of TLR2 could reduce doxorubicin-induced cardiac insufficiency by 20% and inhibit myocardial fibrosis. Here, TLR2 is linked to cardiomyopathy.